ReproCELL Announces New Line of Services in Neuronal Research Using Human iPS Cells

YOKOHAMA, Japan, September 1, 2010 - ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) is pleased to
announce a new line of products to be launched in the autumn of 2010,
offering neuronal cells derived from human iPS (induced pluripotent stem)
cells.

Since April 2009, ReproCELL has been manufacturing iPS
cell-derived cardiomyocytes for drug toxicity testing as the world's first
drug discovery support business provider founded on iPS cells. The
prospective new offering of neuronal cells is the second line of services to
be introduced by the company, and is a considerable expansion of their scope
of business. ReproCELL will be the first in the world to offer iPS cell
derived neuronal cells, and, more specifically, will provide dopaminergic
neurons, motor neurons, and cerebral nerves.

ReproCELL's Representative Director and CEO Chikafumi Yokoyama
PhD commented, "Despite the constant rise of patients with neurodegenerative
disorders such as Alzheimer's and Parkinson's Disease, fundamental therapies
are still sought after in this ageing society. Through offering human iPS
cell derived neuronal cells to the pharmaceutical industry, we hope to enable
more effective screening of various neuroactive therapeutic compounds,
thereby contributing to the development of new medicines."

In addition, the company welcomes its new scientific advisor,
Professor Sian Harding at the National Heart and Lung Institute, Imperial
College London, a leading expert in pluripotent stem-cell derived
cardiomyocytes. Through this new collaboration, the company aims to
accelerate further research and development in the use of iPS cells in this
field.

Website: www.reprocell.net/

Company: ReproCELL Inc., Representative: Chikafumi Yokoyama PhD, Representative Director and CEO, Contact: Tel: +81-(0)45-475-3887, email: info_repro at reprocell.com